U.S.-based clinical-stage biotherapeutics company Tocagen Inc. is planning to secure $30 million in an underwritten public offering.
Tocagen offered to sell 3 million units of its common stock at $10 per unit.
Tocagen granted the underwriters a 30-day option to acquire up to another 450,000 units of its common stock at the same price.
Subjected to customary closing conditions, the deal is expected to close on or about December 17, 2018. U.S.-based investment bank Citigroup and Leerink Partners are acting as joint book-runners on the deal.